Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Gilead acquired Forty Seven for $4.9B for immuno-oncology.
Gilead reassessing magrolimab after FDA placed a partial clinical hold on four mid-stage solid-tumor trials (colorectal, breast, head & neck) in Feb 2024, one…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Gilead acquired Forty Seven for $4.9B for immuno-oncology.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / Forty Seven Inc. (this deal) | 2020 | $4.9B | 18 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Nurix Therapeutics Inc. | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Immunomedics Inc. | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
← Browse all deals · How we score deals
More: 2020 deals · Gilead Sciences Inc. deals · Oncology deals